Saltar al contenido
Merck

An Immune-Competent Murine Model to Study Elimination of AAV-Transduced Hepatocytes by Capsid-Specific CD8

Molecular therapy. Methods & clinical development (2017-05-10)
Brett Palaschak, Damien Marsic, Roland W Herzog, Sergei Zolotukhin, David M Markusic
RESUMEN

Multiple independent adeno-associated virus (AAV) gene therapy clinical trials for hemophilia B, utilizing different AAV serotypes, have reported a vector dose-dependent loss of circulating factor IX (FIX) protein associated with capsid-specific CD8

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
Ensayos de actividad de la ALT, sufficient for 100 colorimetric or fluorometric tests